These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27424224)

  • 1. [Outcomes of patients with juvenile idiopathic arthritis on biological therapy and have a varicella-zoster virus infection].
    Ladino M; Gasitulli A; Muñoz F
    Rev Chil Pediatr; 2017 Apr; 88(2):263-267. PubMed ID: 27424224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.
    Leuvenink R; Aeschlimann F; Baer W; Berthet G; Cannizzaro E; Hofer M; Kaiser D; Schroeder S; Heininger U; Woerner A
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):34. PubMed ID: 27256096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy.
    Toplak N; Avčin T
    Vaccine; 2015 Aug; 33(33):4056-9. PubMed ID: 26144894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay.
    Camacho-Lovillo MS; Bulnes-Ramos A; Goycochea-Valdivia W; Fernández-Silveira L; Núñez-Cuadros E; Neth O; Pérez-Romero P
    Pediatr Rheumatol Online J; 2017 Aug; 15(1):62. PubMed ID: 28784185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
    Nimmrich S; Horneff G
    Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
    Pileggi GS; de Souza CB; Ferriani VP
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1034-9. PubMed ID: 20235203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of varicella zoster virus infection-related myelitis in 10 immunocompetent patients.
    Wang X; Zhang X; Yu Z; Zhang Q; Huang D; Yu S
    J Neuroimmunol; 2018 Aug; 321():36-40. PubMed ID: 29957386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting.
    Brunelli JB; Schmidt AR; Sallum AME; Goldenstein-Schainberg C; Bonfá E; Silva CA; Aikawa NE
    Mod Rheumatol; 2018 Mar; 28(2):264-270. PubMed ID: 28949278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varicella-Zoster Virus Vasculopathy Leading to Multi-Focal Stroke in an Immunocompromised Patient.
    Jang SK; Castillo Almeida NE; Ambroz R; Wilson W
    Am J Med; 2020 Jan; 133(1):e3-e4. PubMed ID: 31351835
    [No Abstract]   [Full Text] [Related]  

  • 11. Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.
    Speth F; Hinze CH; Andel S; Mertens T; Haas JP
    Pediatr Rheumatol Online J; 2018 Mar; 16(1):15. PubMed ID: 29499726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection.
    Alexander KE; Tong PL; Macartney K; Beresford R; Sheppeard V; Gupta M
    Vaccine; 2018 Jun; 36(27):3890-3893. PubMed ID: 29807711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis.
    Nicolai R; Cortis E; Ravà L; Bracaglia C; Pardeo M; Insalaco A; Buonuomo PS; Tozzi AE; De Benedetti F
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):76-9. PubMed ID: 26908493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Varicella-Zoster Virus Infection.
    Kennedy PGE; Gershon AA
    Viruses; 2018 Nov; 10(11):. PubMed ID: 30400213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reactivation of herpes zoster infection by varicella-zoster virus].
    Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M
    Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
    Frenck RW; Seward JF
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):903-6. PubMed ID: 20506363
    [No Abstract]   [Full Text] [Related]  

  • 17. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.
    Ringold S; Weiss PF; Beukelman T; Dewitt EM; Ilowite NT; Kimura Y; Laxer RM; Lovell DJ; Nigrovic PA; Robinson AB; Vehe RK;
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1551-63. PubMed ID: 24078300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment.
    Groot N; Pileggi G; Sandoval CB; Grein I; Berbers G; Ferriani VPL; Wulffraat N; de Roock S
    Vaccine; 2017 May; 35(21):2818-2822. PubMed ID: 28412076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
    Swart JF; de Roock S; Wulffraat NM
    Arthritis Res Ther; 2013; 15(3):213. PubMed ID: 23731900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.